LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article ; Online: Preliminary outcome of Chelidonium majus (greater celandine) for COVID-19.

    Gardin, Nilo E / Braga, Anne Jacqueline

    Phytotherapy research : PTR

    2023  Volume 38, Issue 2, Page(s) 463

    MeSH term(s) Humans ; Chelidonium majus ; COVID-19 ; Chelidonium
    Language English
    Publishing date 2023-02-16
    Publishing country England
    Document type Letter
    ZDB-ID 639136-9
    ISSN 1099-1573 ; 0951-418X
    ISSN (online) 1099-1573
    ISSN 0951-418X
    DOI 10.1002/ptr.7776
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 3092: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Leserbrief. Outcome of Chelidonium majus (greater celandine) for COVID-19

    Gardin, Nilo E. / Braga, Anne Jacqueline

    Der Merkurstab

    2023  Volume 76, Issue 1, Page(s) 53

    Language German
    Document type Article
    ZDB-ID 392536-5
    ISSN 0935-798X
    Database Current Contents Medicine

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4326: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Greater celandine (Chelidonium majus L.) for COVID-19: A twenty-case series.

    Gardin, Nilo E / Braga, Anne Jacqueline

    Phytotherapy research : PTR

    2021  Volume 35, Issue 7, Page(s) 3792–3798

    Abstract: In December 2019, an outbreak of coronavirus disease 2019 (COVID-19) occurred in Wuhan, China, with a rapid increase in cases worldwide. Until now, among several drugs tested, none demonstrated sufficient efficacy for its etiological treatment. Greater ... ...

    Abstract In December 2019, an outbreak of coronavirus disease 2019 (COVID-19) occurred in Wuhan, China, with a rapid increase in cases worldwide. Until now, among several drugs tested, none demonstrated sufficient efficacy for its etiological treatment. Greater celandine (Chelidonium majus L.) is a well-known medicinal plant, traditionally indicated for digestive disorders and topically to remove warts. This study, performed at private offices in São Paulo and Aracaju (Brazil), describes 20 consecutive COVID-19 outpatients treated with greater celandine and their clinical evolution. The patients, aged 14-71 years (median of 41 years), were treated with Chelidonium majus 10% mother tincture, 20-30 drops three times a day for 3-12 days (median of 5 days). Clinical features were assessed during the treatment and at least until 1 week after its end. These cases were considered mild, as most COVID-19 cases. The symptoms were mainly fever, fatigue, cough, sore throat, coryza, anosmia, ageusia, and headache. Ten patients had comorbidities, such as hypertension, diabetes, and overweight. Complete or almost complete clinical improvement occurred within 1-9 days of treatment (median of 3 days). There were no adverse events. This casuistry, although small, may inspire other researchers to continue investigating Chelidonium majus as a healing treatment for COVID-19.
    MeSH term(s) Adolescent ; Adult ; Aged ; Brazil ; COVID-19/drug therapy ; Chelidonium/chemistry ; Diabetes Mellitus, Type 2 ; Female ; Humans ; Male ; Middle Aged ; Plant Preparations/therapeutic use ; Plants, Medicinal/chemistry ; Young Adult
    Chemical Substances Plant Preparations
    Language English
    Publishing date 2021-03-28
    Publishing country England
    Document type Journal Article
    ZDB-ID 639136-9
    ISSN 1099-1573 ; 0951-418X
    ISSN (online) 1099-1573
    ISSN 0951-418X
    DOI 10.1002/ptr.7085
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 3092: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Chelidonium majus and the image of COVID-19

    Gardin, Nilo E. / Grines, Sergio A. / Braga, Anne Jacqueline

    Der Merkurstab

    2021  Volume 74, Issue 5, Page(s) 404

    Language German
    Document type Article
    ZDB-ID 392536-5
    ISSN 0935-798X
    Database Current Contents Medicine

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4326: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Greater celandine (Chelidonium majus L.) for COVID‐19: A twenty‐case series

    Gardin, Nilo E. / Braga, Anne Jacqueline

    Phytotherapy research. 2021 July, v. 35, no. 7

    2021  

    Abstract: In December 2019, an outbreak of coronavirus disease 2019 (COVID‐19) occurred in Wuhan, China, with a rapid increase in cases worldwide. Until now, among several drugs tested, none demonstrated sufficient efficacy for its etiological treatment. Greater ... ...

    Abstract In December 2019, an outbreak of coronavirus disease 2019 (COVID‐19) occurred in Wuhan, China, with a rapid increase in cases worldwide. Until now, among several drugs tested, none demonstrated sufficient efficacy for its etiological treatment. Greater celandine (Chelidonium majus L.) is a well‐known medicinal plant, traditionally indicated for digestive disorders and topically to remove warts. This study, performed at private offices in São Paulo and Aracaju (Brazil), describes 20 consecutive COVID‐19 outpatients treated with greater celandine and their clinical evolution. The patients, aged 14–71 years (median of 41 years), were treated with Chelidonium majus 10% mother tincture, 20–30 drops three times a day for 3–12 days (median of 5 days). Clinical features were assessed during the treatment and at least until 1 week after its end. These cases were considered mild, as most COVID‐19 cases. The symptoms were mainly fever, fatigue, cough, sore throat, coryza, anosmia, ageusia, and headache. Ten patients had comorbidities, such as hypertension, diabetes, and overweight. Complete or almost complete clinical improvement occurred within 1–9 days of treatment (median of 3 days). There were no adverse events. This casuistry, although small, may inspire other researchers to continue investigating Chelidonium majus as a healing treatment for COVID‐19.
    Keywords COVID-19 infection ; Chelidonium majus ; cough ; diabetes ; disease course ; etiology ; fever ; headache ; hypertension ; medicinal plants ; overweight ; pharyngitis ; phytotherapy ; research ; Brazil ; China
    Language English
    Dates of publication 2021-07
    Size p. 3792-3798.
    Publishing place John Wiley & Sons, Ltd.
    Document type Article
    Note JOURNAL ARTICLE
    ZDB-ID 639136-9
    ISSN 1099-1573 ; 0951-418X
    ISSN (online) 1099-1573
    ISSN 0951-418X
    DOI 10.1002/ptr.7085
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 3092: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Allogeneic hematopoietic stem cell transplantation for primary myelodysplastic syndrome Transplante alogênico de células progenitoras hematopoiéticas para síndrome mielodisplásica primária

    Carlos R. Medeiros / Nilo E. Gardin / Ricardo Pasquini

    Revista Brasileira de Hematologia e Hemoterapia, Vol 26, Iss 2, Pp 71-

    2004  Volume 77

    Abstract: Characteristics and outcomes of 52 patients with myelodysplastic syndrome (MDS) who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) were analyzed. Median age was 30 years (range 2-61 years) and median time from diagnosis to allo- ... ...

    Abstract Characteristics and outcomes of 52 patients with myelodysplastic syndrome (MDS) who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) were analyzed. Median age was 30 years (range 2-61 years) and median time from diagnosis to allo-HSCT was 10 months (range 1-161 months). Thirty-six patients had advanced MDS or acute myeloid leukemia following MDS at transplant. Conditioning with busulfan and cyclophosphamide was administered to 73% of patients, and the median value of graft dose was 2.595 x 10(8) of total nucleated cells/kg. Overall survival and disease free survival at 4 years were 36% and 33%, respectively. Nineteen patients were alive, with a median follow-up of 3.8 years. Twelve patients relapsed and only one is alive, after donor lymphocyte infusion. Interval < 6 months between diagnosis and allo-HSCT decreased relapse (P = 0.01). Mortality and relapse were significantly lower among patients with less advanced disease (P = 0.03). Decreased mortality was also observed when transplant occurred after 1994, probably because more patients with less advanced disease received the procedure. Acute GVHD grades > II occurred in 19 patients. Donor type (identical related versus non-related/partially matched related) influenced the incidence of acute GVHD (P = 0.03). Eleven patients developed chronic GVHD and previous acute GVHD was a risk factor (P = 0.03). Thirty-three patients died, 22 (67%) secondary to transplant-related complications. Patients with MDS should undergo allo-HSCT earlier, mainly if they have a compatible donor and are young. Características e resultados de 52 pacientes com síndrome mielodisplásica (MDS) submetidos a transplante alogênico de células progenitoras hematopoiéticas (TCPH) foram analisados. A idade mediana foi de 30 anos (variação de 2-61 anos) e o tempo mediano entre o diagnóstico e transplante foi de dez meses (variação de 1-161 meses). Trinta e seis pacientes tinham MDS avançada ou leucemia mielóide aguda secundária a MDS ao transplante. O condicionamento com busulfano e ciclo­fosfamida foi recebido por 73% dos pacientes, e a dose celular mediana do enxerto foi de 2.56 x 10(8) células nucleadas/kg. A sobrevida global e a sobrevida livre de doença aos quatro anos foi de 36% e 33%, respectivamente. Dezenove pacientes estavam vivos, com um seguimento mediano de 3,8 anos. Doze pacientes recaíram e apenas um deles está vivo, após infusão de linfócitos do doador. Intervalo menor que 6 meses entre o diagnóstico e o transplante reduziu a ocorrência de recaída (P = 0.01). Mortalidade e recaída foram significativamente mais baixas entre os pacientes com doença menos avançada (P = 0.03). Mortalidade mais baixa também foi observada quando o transplante ocorreu após 1994, provavelmente porque mais pacientes com doença menos avançada foram transplantados. Doença do enxerto-contra-hospedeiro (DECH) aguda graus > II ocorreu em 19 pacientes, e sua incidência foi influenciada pela compatibilidade entre doador e paciente (aparentado idêntico versus não-aparentado/aparentado parcialmente compatível) (P = 0.03). Onze pacientes desenvolveram DECH crônica que teve como fator de risco DECH aguda (P = 0.03). Trinta e três pacientes morreram, sendo 22 (67%) de complicações do transplante. Estes dados sugerem que pacientes com MDS devem ser submetidos ao TCPH precocemente, principalmente se são jovens e possuem doador compatível.
    Keywords Síndrome mielodisplásica ; transplante alogênico de células progenitoras hematopoiéticas ; leucemia mielóide aguda ; Myelodysplastic syndrome ; allogeneic hematopoietic stem cell transplantation ; acute myeloid leukemia ; Internal medicine ; RC31-1245 ; Medicine ; R ; DOAJ:Internal medicine ; DOAJ:Medicine (General) ; DOAJ:Health Sciences
    Language English
    Publishing date 2004-01-01T00:00:00Z
    Publisher Sociedade Brasileira de Hematologia e Hemoterapia
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top